Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2018

01-06-2018 | short review

Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting

Author: Univ.-Prof. Dr. Michael Pfeilstöcker, MBA

Published in: memo - Magazine of European Medical Oncology | Issue 2/2018

Login to get access

Summary

Purpose

To review data on acute myeloid leukemia (AML) presented at the 2017 meeting of the American Society of Hematology (ASH) and to discuss these data within the framework of future developments for the disease.

Results and conclusion

Data generated by next generation sequencing (NGS) may be used for primary diagnosis, therapy selection and monitoring as well as characterization of persons at risk for AML development. After validation, this method will need to be implemented in general practice in the future. For treatment more targeted therapies—single agent or in combination with standard chemotherapy or low-dose treatment approaches—will become available and complement our armamentarium against AML. Among others interesting targets discussed are FLT-3, IDH1 and 2, BCL-2, MEK, E‑selectin, MDM2 and JAK1. Furthermore, maintenance after induction chemotherapy is again being considered for the management of AML.
Literature
1.
2.
Pinkal D, Nuria MT, Savenkov O, et al. Acute myeloid leukemia (AML) patients demonstrate increased prevalence of AML-defining mutations in peripheral blood years prior to the development of overt leukemia: a case-control study. Blood. 2017;130(Suppl 1):408.
3.
Abelson S, Ng SWK, Wiessbrod O, et al. Progression to AML is predictable and distinct from age related clonal hematopoiesis. Blood. 2017;130(Suppl 1):471.
4.
Eisfeld AK, Kohlschmidt J, Mrózek K, et al. Mutation patterns identify adult patients with de novo acute Myeloid leukemia (AML) aged 60 years or older who respond favorably to standard chemotherapy:  an analysis of alliance studies. Blood. 2017;130(Suppl 1):103.
5.
Stahl M, Deveaux M, Montesinos P, et al. The impact of the administration schedule and mutational profile on outcomes of patients with relapsed and refractory acute myeloid leukemia treated with hypomethylating agents: a large, international, multi-center analysis. Blood. 2017;130(Suppl 1):148.
6.
Grimm J, Bill M, Jentzsch M, et al. Prognostic impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in complete remission. Blood. 2017;130(Suppl 1):406.
7.
Jongen-Lavrencic M, Grob T, Kavelaars FG, et al. Prospective molecular MRD detection by NGS: a powerful independent predictor for relapse and survival in adults with newly diagnosed AML. Blood. 2017;130(Suppl 1):LBA-5.
8.
Döhner K, Thiede C, Larson RA, et al. Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study. Blood. 2017;130(Suppl 1):467.
9.
Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017;130(Suppl 1):145.
10.
Rollig C, Serve H, Hüttmann A, et al. The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled soraml trial. Blood. 2017;130(Suppl 1):721.
11.
Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients ≤ 60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and Cytarabine/Anthracycline chemotherapy. Blood. 2017;130(Suppl 1):566.
12.
Pratz K, Cherry M, Altman JK, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute Myeloid leukemia (AML). Blood. 2017;130(Suppl 1):722.
13.
Swaminathan M, Kantarjian HM, Daver N, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;130(Suppl 1):723.
14.
DiNardo CD, De Botton S, Stein EM, et al. Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. Blood. 2017;130(Suppl 1):725.
15.
Pollyea DA, Tallman MS, De Botton S, et al. Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). Blood. 2017;130(Suppl 1):638.
16.
DiNardo CD, Stein AS, Fathi AT, et al. Mutant Isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or Ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130(Suppl 1):639.
17.
Stein EM, DiNardo CD, Mims AS, et al. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial. Blood. 2017;130(Suppl 1):726.
18.
Pratz K, Pollyea DA, Jonas BA, et al. Safety and efficacy of venetoclax (VEN) in combination with decitabine or azacitidine in treatment-naive, elderly patients (≥65 years) with acute myeloid leukemia (AML). Haematologica. 2017;102(Suppl 2):175–6.
19.
Wei AH, Strickland SA, Roboz GJ, et al. Updated safety and efficacy results of phase 1/2 study of venetoclax plus low-dose cytarabine in treatment-naive acute myeloid leukemia patients aged ≥65 years and unfit for standard induction therapy. Haematologica. 2017;102(Suppl 2):176.
20.
Wei A, Strickland SA, Roboz GJ, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1‑year outcomes. Blood. 2017;130(Suppl 1):890.
21.
Pollyea DA, Stevens BM, Winters A, et al. Venetoclax (Ven) with azacitidine (Aza) for untreated elderly acute myeloid leukemia (AML) patients (pts) unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies. Blood. 2017;130(Suppl 1):181.
22.
Huls G, Chitu D, Havelange V, et al. Randomized maintenance therapy with azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). Results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). Blood. 2017;130(Suppl 1):463.
23.
Platzbecker U, Middeke JM, Sockel K, et al. Minimal-residual disease guided treatment with azacitidine in MDS/AML patients at imminent risk of relapse: results of the prospective RELAZA2 trial. Blood. 2017;130(Suppl 1):565.
24.
Daver N, Pollyea DA, Yee KWL, et al. Preliminary results from a phase Ib study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R/R) AML. Blood. 2017;130(Suppl 1):813.
25.
DeAngelo DJ, Jonas BA, Liesveld JL, et al. GMI-1271 improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: results of a phase 1/2 study. Blood. 2017;130(Suppl 1):894.
26.
Zeidan AM, Cook RJ, Bordoni R, et al. A phase 1/2 study of the oral novel JAK1 inhibitor INCB052793 as monotherapy and in combination with standard therapies in patients with advanced hematologic malignancies. Blood. 2017;130(Suppl 1):640.
27.
Advani AS, Cooper BW, Visconte V, et al. A phase 1 trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in combination with Ixazomib (MLN9708) for relapsed/ refractory acute myeloid leukemia (AML): final results. Blood. 2017;130(Suppl 1):150.
28.
Uy GL, Rettig MP, Fletcher T, et al. Selinexor in combination with cladribine, cytarabine and G‑CSF for relapsed or refractory AML. Blood. 2017;130(Suppl 1):816.
Metadata
Title
Acute myeloid leukemia—current data from the 2017 American Society of Hematology meeting
Author
Univ.-Prof. Dr. Michael Pfeilstöcker, MBA
Publication date
01-06-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0410-4

Other articles of this Issue 2/2018

memo - Magazine of European Medical Oncology 2/2018 Go to the issue

editorial

Update and clinical highlights presented at the 2017 American Society of Hematology Meeting

editorial

Laboratory diagnostics in hematology—a new “Educational” series

original report

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania

short review

Indolent lymphoma at ASH (American Society of Hematology) 2017: maintenance revisited

editorial

The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy

case report

Pulmonary mass: never judge a book by its cover
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits